Research Article
Very Low-Dose Risperidone in First-Episode Psychosis: A Safe and Effective Way to Initiate Treatment
Table 1
Sociodemographic and illness-related characteristics of the participants ().
| | Fast responders * | Slow responders * | Withdrawn | value |
| Sex (% male) | 75.7% | 69.2% | 75.8% | .81 |
| Mean age at admission, years (SD) | 21.1 (3.7) | 21.6 (4.0) | 21.8 (3.4) | .75 |
| Age at onset of psychotic symptoms, years (SD) | 20.5 (3.5) | 21.0 (3.8) | 21.1 (3.5) | .77 |
| Marital status (% never married) | 81.1% | 80.8% | 90.9% | .44 |
| Education (% post-secondary) | 13.5% | 19.2% | 18.8% | .79 |
| Diagnosis: | | | | | Schizophrenia/schizophreniform | 33 (89.2%) | 19 (73.1%) | 22 (66.7%) | | Schizoaffective/delusional/NOS | 4 (10.8%) | 4 (15.4%) | 5 (15.2%) | | Affective disorder | 0 (0%) | 3 (11.5%) | 6 (18.2%) | .094 |
| Duration of untreated psychosis mean, (SD) and median () days | 225.2 (269.8) | 267.1 (416.5) | 247.5 (370.5) | .97 |
|
|
*Responder status determined after 4 weeks of risperidone at a dose of 2 mg/day.
|